{"filing":{"accession_number":"0001193125-26-389400","cik":"0001070494","ticker":"ACAD","company_name":"ACADIA PHARMACEUTICALS INC","form":"8-K","filing_date":"2026-09-11","report_date":"2026-09-11","primary_document":"d143428d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1070494/000119312526389400/d143428d8k.htm"},"events":[{"id":33022,"run_id":30353,"accession_number":"0001193125-26-389400","anchor_item_number":"8.01","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.92,"summary":"This disclosure reports preliminary court approval of a settlement in a stockholder derivative action (Kanner et al. v. Biggar et al.) against Acadia's officers and directors, with a $1.5 million attorneys' fee award and mandatory adoption of corporate governance reforms for four years. The settlement resolves allegations of breach of fiduciary duty, unjust enrichment, and insider trading related to false statements about the pimavanserin sNDA deficiency and complete response letters that caused a 45%+ stock price decline. This is a material litigation settlement with significant governance consequences.","company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","filing_date":"2026-09-11","form":"8-K","submitted_at":null,"items":[{"id":36348,"accession_number":"0001193125-26-389400","item_number":"8.01","item_title":"Other Events.","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.92,"reasoning":"This disclosure reports preliminary court approval of a settlement in a stockholder derivative action (Kanner et al. v. Biggar et al.) against Acadia's officers and directors, with a $1.5 million attorneys' fee award and mandatory adoption of corporate governance reforms for four years. The settlement resolves allegations of breach of fiduciary duty, unjust enrichment, and insider trading related to false statements about the pimavanserin sNDA deficiency and complete response letters that caused a 45%+ stock price decline. This is a material litigation settlement with significant governance consequences.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T21:15:45.428443+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36348,"accession_number":"0001193125-26-389400","item_number":"8.01","item_title":"Other Events.","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.92,"reasoning":"This disclosure reports preliminary court approval of a settlement in a stockholder derivative action (Kanner et al. v. Biggar et al.) against Acadia's officers and directors, with a $1.5 million attorneys' fee award and mandatory adoption of corporate governance reforms for four years. The settlement resolves allegations of breach of fiduciary duty, unjust enrichment, and insider trading related to false statements about the pimavanserin sNDA deficiency and complete response letters that caused a 45%+ stock price decline. This is a material litigation settlement with significant governance consequences.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T21:15:45.428443+00:00","company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","filing_date":"2026-09-11"}]}